The oncogene Bcl-2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease. However, the molecular mechanism underlying androgenic regulation of Bcl-2 in prostate cancer cells is understood poorly. In this study, we demonstrated that no androgen response element (ARE) was identified in the androgen-regulated region of the P1 promoter of Bcl-2 gene, whereas, we provided evidence that the androgenic effect is mediated by E2F1 protein through a putative E2F-binding site in the promoter. We further demonstrated that retinoblastoma (RB) protein plays a critical role in androgen regulation of Bcl-2. The phosphorylation levels of RB at serine residues 780 and 795 were decreased in LNCaP cells treated with androgens. Ectopic expression of a constitutively active form of RB inhibited expression of Bcl-2. Knockdown of endogenous RB protein by an Rb small inference RNA (siRNA) induced an increase in Bcl-2 levels. Most importantly, the effect of androgens on Bcl-2 was abolished completely by specific inhibition of RB function with a mutated E1A. Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclindependent kinase inhibitors (CDKIs) p15INK4B and p27KIP1. Ectopic expression of p15INK4B and/or p27KIP1 inhibited Bcl-2 expression. Knockdown of endogenous p15INK4B or p27KIP1 protein with a pool of siRNAs diminished androgen-induced downregulation of Bcl-2 expression. Therefore, our data indicate that androgens suppress Bcl-2 expression through negatively modulating activities of the E2F site in the Bcl-2 promoter by activating the CDKI-RB axis.
The oncogene Bcl-2 is upregulated frequently in prostate tumors following androgen ablation therapy, and Bcl-2 overexpression may contribute to the androgen-refractory relapse of the disease. However, the molecular mechanism underlying androgenic regulation of Bcl-2 in prostate cancer cells is understood poorly. In this study, we demonstrated that no androgen response element (ARE) was identified in the androgen-regulated region of the P1 promoter of Bcl-2 gene, whereas, we provided evidence that the androgenic effect is mediated by E2F1 protein through a putative E2F-binding site in the promoter. We further demonstrated that retinoblastoma (RB) protein plays a critical role in androgen regulation of Bcl-2. The phosphorylation levels of RB at serine residues 780 and 795 were decreased in LNCaP cells treated with androgens. Ectopic expression of a constitutively active form of RB inhibited expression of Bcl-2. Knockdown of endogenous RB protein by an Rb small inference RNA (siRNA) induced an increase in Bcl-2 levels. Most importantly, the effect of androgens on Bcl-2 was abolished completely by specific inhibition of RB function with a mutated E1A. Finally, androgen treatment of LNCaP cells upregulated specifically levels of the cyclindependent kinase inhibitors (CDKIs) p15INK4B and p27KIP1. Ectopic expression of p15INK4B and/orIntroduction Androgens, functioning through activation of the transcriptional activity of the androgen receptor (AR), are important not only for the development and function of the normal prostate gland, but also for the proliferation and survival of androgen-sensitive andrefractory prostate cancer cells (Grossmann et al., 2001; Huang and Tindall, 2002; Zegarra-Moro et al., 2002) . Surgical or pharmaceutical ablation of testicular androgens has been the most effective treatment of metastatic prostate cancer since 1941 (Huggins and Hodge, 1941) . Both normal and malignant epithelial cells of the prostate undergo programmed cell death (apoptosis) in the absence of androgens (Isaacs, 1984; Kyprianou et al., 1990) . However, a majority of prostate cancer patients usually relapse with tumors becoming refractory to androgen ablation therapy, suggesting that relapsed cells are able to resist androgen withdrawal-induced cell death (Denmeade et al., 1996) . One of the antiapoptotic factors that favors the survival of androgen-refractory prostate cancer cells may involve overexpression of Bcl-2 (McDonnell et al., 1992; Colombel et al., 1993; Krajewska et al., 1996) . Bcl-2 protein is expressed intensely in 77% of androgen-refractory prostate tumors compared to 32% in androgen-sensitive tumors (McDonnell et al., 1992 (McDonnell et al., , 1997 Westin et al., 1995) .
Bcl-2 belongs to a family of proteins that includes the antiapoptotic subfamily (e.g. Bcl-2, Bcl-xL, and Mcl-1), the proapoptotic subfamily (e.g. Bax, Bak, and Bok), and the BH3-only subfamily (e.g. Bid, Bim, and Noxa) (Green, 2000) . The pro-and antiapoptosis counterparts of this family form heterodimers and titrate out each other's functions, suggesting that their relative concentrations play a pivotal role in execution of programmed cell death. Overexpressed Bcl-2 protein increases the level of Bcl-2/Bax heterodimer, stabilizes the integrity of mitochondria, and protects cells from apoptosis (Haldar et al., 1997) .
Direct evidence suggesting that the Bcl-2 protein facilitates survival of prostate cancer cells in an androgen-depleted environment has been obtained by a number of functional studies. Tumor xenografts from Bcl-2-transfected LNCaP cells are resistant to the antitumor effect of castration; whereas tumors from nontransfected LNCaP cells are inhibited by androgen deprivation (Raffo et al., 1995) . Additionally, disruption of intracellular Bcl-2 mRNA by means of antisense RNA or a hammerhead ribozyme effectively delays or inhibits androgen-refractory growth of the cell line LNCaP, the Shionogi tumor, and tumors in patient with metastatic androgen-refractory prostate cancer (Dorai et al., 1997a, b; Gleave et al., 1999a, b; Miyake et al., 1999; Chi et al., 2001) . Moreover, Bcl-2 may play a role in prostate cancer progression by decreasing cell proliferation and stimulating angiogenesis (Westin et al., 1995; Fernandez et al., 2001) .
It is possible that the increased expression of Bcl-2 in androgen-refractory prostate cancer may result from outgrowth of cells expressing high levels of Bcl-2 before androgen ablation treatment. It is also possible, but not necessarily mutually exclusive that androgen ablation may reset the regulatory effect of androgens on Bcl-2 expression in androgen-responsive cells. In fact, levels of Bcl-2 transcripts increase in the rat prostate following castration (McDonnell et al., 1992) . Moreover, this increase is abrogated in castrated rats that receive testosterone. Expression of Bcl-2 mRNA is elevated in LNCaP xenografts in castrated mice. In contrast, androgen treatment of LNCaP cells results in downregulation of Bcl-2 (Gleave et al., 1999a) . These data suggest that androgens inhibit Bcl-2 expression in prostatic cells regardless whether they are normal or malignant. However, the regulatory mechanism is unknown. The current study was undertaken to dissect the cellular pathway(s) that mediate androgenic regulation of expression of the Bcl-2 gene in cancerous prostatic cells.
Results

Androgens inhibit Bcl-2 expression through a mechanism dependent on the AR
We have demonstrated previously that LNCaP prostate cancer cells undergo dynamic morphological and biochemical changes such as neuroendocrine differentiation when cultured in androgen-depleted media (Murillo et al., 2001) . To examine the effect of androgens on Bcl-2 expression, LNCaP cells were incubated in regular culture medium, plus/minus physiological concentrations of androgens. Treatment of LNCaP cells with 1 or 5 nM of the synthetic androgen R1881 resulted in a decreased expression of Bcl-2 protein (Figure 1a ). The effect of androgens on LNCaP cells was evident by an increase in expression of prostate-specific antigen (PSA) (Figure 1a) . Since no apoptotic cell death was observed in androgen-treated cells, we examined the effect of androgens on levels of the proapoptotic protein Bax. Similar to a previous finding (Kimura et al., 2001) , androgen treatment resulted in a decrease in Bax protein (Figure 1a) . It has been shown previously that Figure 1 The effects of androgens on expression of Bcl-2 protein in LNCaP (a) and PC-3 (b) prostate cancer cells. (a) LNCaP cells grown in culture medium were treated with R1881 (1 or 5 nM) or vehicle (ETOH) for 48 h. Whole-cell lysates were prepared. Aliquots (50 mg) were separated by 4-12% SDS-PAGE under reducing conditions. Immunoblotting was performed using antibodies to Bcl-2, Bax, and PSA, respectively. For an internal control, the blots were stripped and reprobed with an antibody to extracellular signal-regulated kinase 2 (Erk2). (b) PC-3 cells (1 Â 10 6 ) in log phase were transfected with an AR expression vector (1 or 2 mg) or an empty vector. At 24 h following transfection, cells were treated with 1 nM of R1881 ( þ ) or ETOH (À). After 48 h of androgen treatment, cells were lysated and analysed for expression of AR, Bcl-2, Skp2, and Erk2 proteins. These experiments were repeated for three times. (c) A quantitative analysis of signal intensity of the Bcl-2 protein in cells treated with androgen versus vehicle (ETOH). The relative Bcl-2 protein levels in LNCaP or PC-3 cells treated with 1 nM of R1881 was presented by normalizing the signal intensity of Bcl-2 to Erk2 first, then to the normalized value of Bcl-2 in cells treated with vehicle. Data are from a representative experiment performed three times Androgens inhibit Bcl-2 expression via RB H Huang et al expression of the F-box protein Skp2 is downregulated by androgens in LNCaP cells (Lu et al., 2002) . As shown in Figure 1b , expression of Skp2 in PC-3 cells transfected with an AR expression construct was decreased by androgen treatment, suggesting that the androgen signaling axis is functional in these cells. To determine whether the effect of androgens on Bcl-2 is mediated by the AR, AR-negative PC-3 prostate cancer cells were transiently transfected with a human AR expression vector. As shown in Figure 1b , androgens not only stabilized the AR protein, but also caused a decrease in Bcl-2 expression in the presence of the AR. However, there was no effect of AR alone on Bcl-2 expression even at a higher level of the protein (Figure 1b , lane 4). Quantitative analysis of signal intensity demonstrated that androgen treatment (1 nM of R1881), resulted in more than 50% reduction in Bcl-2 protein in both LNCaP and PC-3 cells, although the reduction in PC-3 cells was slightly less than in LNCaP cells ( Figure 1c ). Thus, these findings suggest that androgen regulation of Bcl-2 expression is mediated through the AR.
Androgens inhibit activity of the Bcl-2 promoter through a putative E2F site
Since androgen regulation of Bcl-2 requires the AR, we sought to determine whether or not androgens transcriptionally regulate Bcl-2 expression. As shown in Figure 2a , treatment of LNCaP cells with 1 nM of R1881 resulted in a decrease in Bcl-2 messenger RNA. To determine whether androgens repress Bcl-2 expression via a direct mechanism, we cotreated cells with R1881 and cycloheximide, an inhibitor of de novo protein synthesis. As shown in Figure 2a , the effect of androgens on Bcl-2 expression was abolished by pretreatment of cells with cycloheximide. The inhibitory effect of cycloheximide on protein synthesis was confirmed indirectly by the blockage of androgenic induction of expression of fatty acid synthase (data not shown), a gene that is coordinately regulated by androgens (Swinnen et al., 1997) . Thus, these data suggest that the androgenic effect on Bcl-2 mRNA is mediated through an indirect mechanism. In order to identify the regulatory effector(s) of androgens on Bcl-2 expression, we performed promoter reporter assays. Previous studies have shown that two promoters, namely P1 and P2, control transcription of the Bcl-2 gene. Studies done in many different cell types demonstrate that fewer than 5% of all Bcl-2 transcripts are initiated from the P2 promoter (Seto et al., 1988; Tsujimoto and Croce, 1986; Miyashita et al., 1994; Wilson et al., 1996; Huang et al., 2001; Huang and Tindall, 2002) , suggesting that P1 is the predominant promoter of the Bcl-2 gene. Indeed, results from us and others have shown previously that PTEN and WT1 inhibits Bcl-2 expression through the P1 promoter in LNCaP cells Cheema et al., 2003) . Therefore, in this study we focused on the effect of androgens on regulation of the P1 promoter. LNCaP cells were transiently transfected with a panel of luciferase reporter constructs containing various regions of the P1 promoter. As shown in Figure 2b , luciferase activities of reporter constructs LB124 and LB334 were inhibited approximately 50% in cells treated with 1 nM of R1881, whereas, the activity of the reporter plasmids pBcl2m-Luc and LB360 were unaffected. These data suggest that transcriptional activity of the Bcl-2 gene is downregulated by androgens, and that an androgen regulatory region exists between nucleotides (nts) À1532 and À1343 of the P1 promoter. Consistent with our previous finding that androgens regulate Bcl-2 expression through an indirect mechanism, there is no androgen response element (ARE) found in this 190 bp androgen-regulated region. Therefore, we performed systemic mutation analyses in several candidate regulatory elements within this region. We found that mutations in an E2F site (À1452 to À1445), which was characterized previously in the promoter of the p21WAF1 gene (Hiyama et al., 1998) , impaired the basal activity of the Bcl-2 promoter in normal culture conditions ( Figure 2c , gray column). Importantly, luciferase activity of this reporter gene was reduced by 50% in cells treated with 1 nM of R1881 (Figure 2c , black column in the middle). This inhibition was similar to that observed with constructs LB124 and LB334 ( Figure 2b ). As shown in Figure 2c , mutations in the E2F site [pBcl2(mE2F-v)] abrogated the androgenic inhibition of this reporter construct. These data suggest that regulation of Bcl-2 expression by androgens is mediated by E2F proteins.
E2F1 transactivates the promoter of the Bcl-2 gene in prostate cancer cells
To verify that the E2F site in the Bcl-2 promoter is involved in the androgen regulation of Bcl-2 expression, we determined whether E2F1 regulates expression of the Bcl-2 gene in prostate cancer cells. As shown in Figure 3a and b, ectopic expression of E2F1 in LNCaP cells resulted in increases in Bcl-2 protein and mRNA. Moreover, transcriptional activity of the Bcl-2 promoter was increased approximately fivefold by ectopic expression of E2F1, and this activity was markedly decreased when mutations were introduced into the E2F-binding site (Figure 3c ). Chromatin immunoprecipitation (ChIP) assays demonstrated that E2F1 binds to the promoter of the Bcl-2 gene in vivo (Figure 3d ). Thus, these data provide direct evidence that E2F1 binds to and transactivates the promoter of the Bcl-2 gene.
E2F1 is a mediator of androgen-induced suppression of Bcl-2 expression Next we determined whether the E2F1 protein is a mediator of the androgen-induced suppression of Bcl-2 expression. Androgen treatment of LNCaP cells resulted in a decrease in levels of E2F1 protein (Figure 4a ). In line with the decrease in E2F1 protein, two known E2F1-transactivated genes, p107 and cyclin A (Vigo et al., 1999) , were also decreased in the cells treated with androgen (Figure 4a ), suggesting that a decrease in E2F1 transcriptional activity is associated with the downregulation of E2F1 protein induced by androgens. A robust effect of androgens on expression of cyclin A has been observed with high dose dihydrotestosterone (100 nM) (Tsihlias et al., 2000) . As demonstrated in ) in log phase were transiently transfected with 2 mg of luciferase reporter plasmids of the Bcl-2 promoter by electroporation. At 12 h after transfection, cells were treated with 1 nM of R1881 or ETOH for 24 h. Firefly luciferase activities were measured. A renilla luciferase vector was used as an internal control. Activity of the reporter construct in androgen-treated cells was normalized to renilla luciferase activity, empty backbone reporter activity, and then to the activity of these reporter constructs in cells treated with vehicle (ETOH). Data represent the mean values þ standard deviation of three independent experiments. (c) The top panel shows a schematic diagram of luciferase reporter constructs of the Bcl-2 promoter pBcl2(E2F-v) and pBcl2(mE2F-v) as well as the backbone pGL3 promoter luciferase vector (pGL3-Prom) that contains an SV 40 min promoter upstream of the luciferase gene. The plasmids pBcl2(E2F-v) and pBcl2(mE2F-v) contain a wild-type (CTCCGCGC) and mutated (CTCCGATC) putative E2F-binding site, respectively. The bottom panel shows the effect of androgens on the activities of these reporter genes. LNCaP cells (1 Â 10 6 ) were transfected with 2 mg of the luciferase reporter plasmids by electroporation. At 12 h after transfection, cells were treated with 1 nM of R1881 or ETOH for 24 h. Firefly luciferase activities were measured. The luciferase activities of the Bcl-2 promoters were normalized by values of the backbone vector pGL3-Prom. A renilla luciferase vector was used as an internal control. Data represent the mean values þ standard deviation of three independent experiments Androgens inhibit Bcl-2 expression via RB H Huang et al abrogated completely by pretreatment of cells with cycloheximide, an inhibitor of protein synthesis, or actinomycin D, an inhibitor of RNA synthesis ( Figure 4c ). These data suggest that androgen-induced downregulation of E2F1 is not mediated directly by the AR. These findings also rule out the possibility that the androgenic effect is mediated by a mechanism of mRNA stability. Next, we examined the effects of androgens on the transcriptional activity of E2F1 promoter reporter constructs. We found that the activities of a number of reporter constructs containing up to 728 bp of the E2F1 promoter, were inhibited by androgen treatment (Figure 4d ). All of these constructs include a region that contains two E2F consensus-binding sites (see Figure 4d ) that is known to mediate autoregulation of E2F1 expression. Thus, androgens may downregulate E2F1, which in turn downregulates Bcl-2 expression. To test this possibility, we transiently transfected an E2F1 expression vector into LNCaP cells. As shown in Figure 4e , transfection of an E2F1 expression plasmid increased the levels of E2F1 protein. Importantly, elevated levels of E2F1 blocked the androgen-induced decrease in Bcl-2 expression (Figure 4e ), suggesting that E2F1 is mediating the androgenic effects on Bcl-2 expression. To further test this under more physiological conditions, we established a subline of LNCaP, which stably expresses exogenous E2F1. We found that the androgen-induced decrease in Bcl-2 expression was largely abrogated by high levels of E2F1 protein (Figure 4f ), supporting the results obtained from the transient transfection experiments. To determine whether the regulation of Bcl-2 by E2F1 is mediated through the AR itself, we examined the protein levels of AR and PSA. As shown in Figure 4e , androgen treatment resulted in an increase in the levels of both AR and PSA proteins regardless of ectopic expresion of E2F1. A similar result was observed in a cell line stably , and the bottom panel shows the PCR results obtained from input samples (Input). PCR amplifications from water (H 2 O) and a 2.6 kb genomic DNA fragment of the Bcl-2 promoter (LB124, see Materials and methods) were performed as a negative or positive control, respectively. Data are from a representative experiment performed three times Figure 4 The effect of E2F1 expression on androgen-induced suppression of Bc-2. (a) Effect of androgens on expression of E2F1 and E2F1-regulated proteins, p107 and cyclin A, in LNCaP cells. LNCaP cells grown in culture medium were treated with R1881 (1 or 5 nM) or vehicle (ETOH) for 48 h. Whole-cell lysates were prepared. Aliquots (50 mg) were separated by SDS-PAGE under reducing conditions. Immunoblotting was performed using antibodies to E2F1, p107, and cyclin A. For internal loading controls, the blots were stripped and reprobed with an antibody to extracellular signal-regulated kinase 2 (Erk2). (b) Effect of androgens on E2F1 expression in PC-3 cells. Cells (1 Â 10 6 ) in log phase were transfected with an AR expression vector (1 or 2 mg). At 24 h following transfection, cells were treated with R1881 (1 nM) or ETOH. After 48 h of androgen treatment, cells were lysated and analysed for expression of AR, and E2F1. (c) Androgen effect on expression of E2F1 mRNA in LNCaP cells. LNCaP cells, pretreated with 25 mg/ml of cycloheximide (CHX), 4 mM of actinomycin D (ActD) or mock (ETOH) for 30 min, were treated with 1 nM of R1881 or ETOH for 24 h. Total cellular RNA were isolated using the TRIZOL reagent. The androgenic effects the expression of E2F1 mRNA were analysed by Northern blot hybridization. Expression of the housekeeping gene GAPDH was utilized as a loading control. (d) Effect of androgens on transcription of E2F1 in LNCaP cells. LNCaP cells (1 Â 10 6 ) were transiently transfected with 2 mg of luciferase reporter plasmids of the promoter of the human E2F1 gene by electroporation. At 12 h after transfection, cells were treated with 1 nM of R1881 or ETOH for 24 h. Firefly luciferase activities were measured. A renilla luciferase vector was used as an internal control. Changes in activity of the reporter construct in androgen-treated cells was determined by normalizing light units to renilla luciferase activity, empty backbone reporter activity, and then to the activity of these reporter constructs in the cells treated with vehicle (ETOH). Data represent the mean values þ standard deviation of three independent experiments. (e) Transient transfection of LNCaP cells with E2F1 abrogated androgenic inhibition of Bcl-2 expression. LNCaP cells were transiently transfected with an E2F1 expression plasmid (1 mg). At 24 h post-transfection, cells were treated with R1881 or ETOH for 48 h. Expression of E2F1, Bcl-2, AR, and PSA proteins were analysed by Western bot. (f) Stable expression of E2F1 in LNCaP cells diminished androgenic suppression of Bcl-2. Stable clones for E2F1 or empty vector with a Neo gene were selected from transfections. Different clonal lines of cells stably transfected with the E2F1 or Neo gene were combined and treated with R1881 or ETOH. At 48 h after treatment, expression of E2F1, Bcl-2, AR, and PSA were analysed by Western blot. Data are from a representative experiment performed three times Androgens inhibit Bcl-2 expression via RB H Huang et al expressing E2F1 (Figure 4f ). Taken together, these data confirm that E2F1 is a mediator of androgenic suppression of Bcl-2 expression.
Androgenic inhibition of Bcl-2 expression is mediated by activation of the RB protein E2F1 is known to be a target of the retinoblastoma (RB) protein. RB binds physically to E2F1 and silences its function. It was therefore of interest to determine whether the RB protein is involved in the androgenic downregulation of E2F1 and whether this might lead to decreased expression of Bcl-2. Treatment of LNCaP cells with 1 or 5 nM of R1881 resulted in activation of RB protein as indicated by loss of hyperphosphorylated RB proteins (Figure 5a ). This finding was confirmed by observations of decreased phosphorylation at serine residues 780 and 795, which are known to be critical sites for RB activation (Figure 5a ). To determine whether activation of the RB protein affects expression of Bcl-2, LNCaP cells were transiently transfected with a constitutively active form of RB (RbDK11), in which 11 cyclin-dependent kinase (CDK)-regulated phosphorylation sites are mutated (Jiang and Zacksenhaus, 2002) . Ectopic expression of this constitutively active form of RB resulted in a decrease in levels of Bcl-2 proteins ( Figure 5b ). The activation of RB was evident by the fact that ectopic expression of RB resulted in a decrease in the level of the E2F1 protein ( Figure 5b ). This effect was abolished by cotransfection with a mutated form of E1A, RG2 that inhibits specifically RB function (Liu et al., 2000) . Ectopic expression of the constitutively active RB vector, RbDK11, resulted in a decrease in the activity of the wild-type Bcl-2 promoter reporter construct pBcl2(E2F-v) but not the construct with a mutated E2F site [pBcl2(mE2F-v) ( Figure 5c ). These data indicate that androgens and RB regulate the expression of Bcl-2 through the same pathway, suggesting that androgen-induced downregulation of Bcl-2 may be mediated by activating the RB protein.
To further verify the inhibitory effect of RB activation on Bcl-2 expression, we determined whether knockdown of endogenous RB causes increased expression of Bcl-2. To this end, we microinjected a small interference RNA (siRNA) of the Rb gene into LNCaP cells. The levels of RB protein in cells microinjected with the siRNA were reduced markedly (Figure 6a , second column in the lower panel), while Bcl-2 levels were increased (lower panel) compared to the levels of Bcl-2 in cells Figure 5 The effect of RB function on Bcl-2 expression in LNCaP cells. (a) Androgen regulation of RB phosphorylation. LNCaP cells in log phase were treated with R1881 (1 or 5 nM) or ETOH for 48 h. Whole-cell lysates were prepared. A measure of 50 mg of proteins from each sample were separated by 6% SDS-PAGE under reducing conditions. Immunoblotting was performed using antibodies to pan RB proteins, which include those that are hyperphosphorylated (Hyper-p-RB) or hypophosphorylated (Hypo-p-RB), and to proteins specifically phosphorylated at the serine 780 (Ser780-p-RB) and the serine 795 (Ser795-p-RB). (b) LNCaP cells (1 Â 10 6 ) were cotransfected with an expression vector for a constitutively active form of RB (pcDNA3-RbDK11) and RG2, a mutant E1A, or an empty vector pCI. At 48 h post-transfection, whole-cell lysates were prepared. A measure of 50 mg of proteins from each sample were separated by 4-12% SDS-PAGE under reducing conditions. Immunoblotting was performed using a monoclonal antibody to RB, E2F1, and Bcl-2. Previous studies have demonstrated that the adenoviral protein E1A binds to and inactivates both RB and CBP/p300 (Liu et al., 2000) . When an Arg-Gly mutation at position-2 (referred to as RG2) is introduced into E1A, it retains the ability to inhibit RB activation, but loses the ability to inhibit CBP/p300 (Liu et al., 2000) . Another mutant of E1A (referred to as YH47/CG124) is known to inhibit CBP/p300, but loses its ability to inactivate RB (Liu et al., 2000) (Figure 7a ). Therefore, we examined the effects of E1A and the mutant forms of the protein on androgen-induced inhibition of Bcl-2. As shown in Figure 7b , ectopic expression of wild-type E1A in LNCaP cells abolished completely the androgen-induced decrease in expression of Bcl-2. When RG2 was transfected into LNCaP cells the androgen-induced decrease in Bcl-2 was abrogated (Figure 7b ). However, when YH47/CG124 was transfected, androgen-induced decreases in Bcl-2 expression were retained (Figure 7b ). The effect of E1A proteins was evident by their downregulation of E2F1 protein (Figure 7b, upper panel) . Taken together, these data suggest that activation of the RB protein plays an essential role in the androgenic inhibition of Bcl-2 expression in LNCaP cells. The role of other members of the RB family, such as p107 and p130, in the androgen regulation of Bcl-2 expression is currently under investigation.
The role of p15INK4B and p27KIP1 in androgenic suppression of Bcl-2 expression
The results described above demonstrated that androgens inhibit phosphorylation of RB at serine 780 and serine 795 (Figure 5a ). Since RB is phosphorylated and inactivated at these two sites by CDKs, including CDK2 and CDK4/6, we examined whether physiological concentrations of androgens affect expression of the cyclin-dependent kinase inhibitors (CDKIs) including p15INK4B, p16INK4, p21WAF1, and p27KIP1. As shown in Figure 8a , treatment of LNCaP cells with androgens resulted in a marked increase in both p15INK4B and p27KIP1. In contrast, levels of p16INK4 decreased slightly in cells treated with androgens. No effect of androgens on expression of the p21WAF1 protein was observed. To determine whether or not translation/transcription is required for the androgen-induced increase in p15INK4B and p27KIP1 levels, we performed Northern hybridization analyses. As shown in Figure 8b , a moderate increase in p15INK4B mRNA was observed in the cells treated with 1 nM of R1881. In contrast, there was no change in levels of p27KIP1 mRNA detected after androgen treatment. Results from luciferase reporter gene assays demonstrated that androgens stimulated approximately a twofold increase in a reporter gene containing the p15INK4B promoter (Figure 8c ). Moreover, androgen treatment resulted in an increase in the stability of the p27KIP1 protein (Figure 8d ). Thus, these data suggest that androgens regulate expression of p15INK4B at the transcriptional level, whereas androgens affect expression of p27KIP1 at a post-transcriptional level. In order to determine whether androgen-induced upregulation of p15INK4B and p27KIP1 plays an essential role in androgen-mediated suppression of Bcl-2, we examined directly the effect of these two proteins on Bcl-2 expression. As shown in Figure 9a , ectopic expression of p15INK4B resulted in decreased levels of the Bcl-2 protein. Forced expression of p15INK4B also caused downregulation of E2F1 expression and RB phosphorylation at both serine 780 and serine 795. Ectopic expression of p27KIP1 resulted in a decrease in Bcl-2 expression, but to a lesser extent than that observed with p15INK4B. In line with this, expression of p27KIP1 caused only a slight decrease in the levels of the E2F1 protein as well as a decrease of RB phosphorylation only at serine 795, but not serine 780 (Figure 9a) . A synergistic effect was seen on Bcl-2 expression by cotransfection of p15INK4B and p27KIP1 into LNCaP cells (Figure 9a ). To determine whether p15INK4B and p27KIP1 regulate Bcl-2 expression through the E2F site in the promoter of the Bcl-2 gene, LNCaP cells were transfected with Bcl-2 promoter reporter constructs containing either wild-type or mutated E2F-binding site. As shown in Figure 9b , forced expression of p15INK4B, p27KIP1, or both, decreased the activity of the wild-type reporter construct. However, little or no inhibitory effect was detected with the mutant reporter construct (Figure 9b ). These results indicate that the effects of p15INK4B and p27KIP1 on expression of the Bcl-2 gene are mediated through the E2F site in the Bcl-2 promoter. To further prove that p15INK4B or p27KIP1 play an important role in androgen regulation of Bcl-2 expression, LNCaP cells were transiently transfected with siRNAs against the p15INK4B or p27KIP1 gene prior to exposure with androgens. As shown in Figure 9c , transfection of a pool of siRNAs of p15INK4B largely reduced the effect of androgens on p15INK4B expression compared to cells transfected with a nonspecific siRNA pool. Consistent with this finding, androgen-induced downregulation of both E2F1 and Bcl-2 was diminished by the p15INK4B siRNAs (Figure 9c) . A similar result was obtained in experiments where expression of p27KIP1 was inhibited with a pool of p27KIP1 siRNAs (Figure 9d ). Therefore, our data suggest that androgen-mediated elevation in the levels of p15INK4B and p27KIP1 play a critical role in the regulation of Bcl-2 in LNCaP cells.
The effect of androgens on Bcl-2 expression is independent of androgen-induced G1 arrest
Both RB and E2F1 proteins are critical in regulation of the cell cycle in mammalian cells. Also, high concentrations of androgens are known to induce cell cycle arrest at G0/G1 (Tsihlias et al., 2000) . Therefore, we sought to determine the kinetics of Bcl-2 and E2F1 expression in relationship to the cell cycle in androgen-treated LNCaP cells. As indicated in Figure 10a , no changes in cell cycle were observed at 6 or 12 h after androgen treatment, whereas at 24 h after treatment, a significant increase in the number of cells in G0/G1 and a significant decrease in the number of cells in S phase were observed. Levels of E2F1 and Bcl-2 proteins started to decrease at 12 h following androgen treatment (Figure 10b ). Thus, these data indicate that androgen-induced downregulation of Bcl-2 is independent of androgen-induced cell cycle arrest. 
Discussion
In the present study, by transducing the AR into the AR-null PC-3 cells, we demonstrate that androgeninduced suppression of Bcl-2 expression relies on expression of the AR. However, the inhibitory effect of androgens does not result directly from the binding of the AR to the Bcl-2 promoter, since the effect of androgens on Bcl-2 expression was abolished by protein synthesis. This was further supported by the finding that no ARE is found in the androgen-regulated region of the P1 promoter identified in this study. Importantly, mutation analyses of the androgen-regulated region demonstrated that the androgenic inhibiton acts through a putative E2F site in the P1 promoter. We demonstrated for the first time that E2F1 binds to this element in a natural setting by ChIP assays. In line with these findings, androgen treatment of LNCaP cells resulted in a decrease in E2F1 expression and ectopic expression of E2F1 blocked androgen-induced downregulation of Bcl-2. Moreover, we provide evidence that the inhibitory effect of androgens on Bcl-2 expression is mediated upstream of E2F1 by upregulation of p15INK4B and p27KIP1 and activation Figure 8 The effect of androgens on expression of p15INK4B and p27KIP1. (a) Androgens upregulate expression of p15INK4B and p27KIP1 proteins in LNCaP cells. Cells grown in culture medium were treated with R1881 or (ETOH) for 48 h. Whole-cell lysates were prepared. A measure of 50 mg of proteins from each sample were separated by 4-12% SDS-PAGE under reducing conditions. Immunoblotting was performed using antibodies against p15INK4B, p16INK, p21WAF1, and p27KIP1. For an internal control, the blots were stripped and reprobed with an Erk2 antibody. (b) Androgen regulation of expression of p15INK4B and p27KIP1 mRNA in LNCaP cells. Cells grown in log phase were treated with 1 nM of R1881 or ETOH for 48 h. Total cellular RNA were isolated using the TRIZOL reagent. The effect of androgens on expression of p15INK4B or p27KIP1 mRNA was examined by Northern blot analysis. Expression of the housekeeping gene GAPDH was utilized as a loading control. (c) LNCaP cells (1 Â 10 6 ) were transfected by electroporation with 2 mg of the luciferase reporter plasmids. At 24 h after transfection, cells were treated with 1 nM of R1881 or ETOH for 36 h. Firefly luciferase activitiy of p15P751-luc reporter gene was measured. A renilla luciferase vector was used as an internal control. The normalized luciferase activity of pGL2-Basic vector in the absence of androgens is designated arbitrarily as one. Data represent the mean values þ standard deviation of three independent experiments. (d) Exponentially growing LNCaP cells were treated with 1 nM of R1881 or ETOH for 36 h, followed by 15 mg/ml of cycloheximide (time zero) and protein samples were collected at the indicated time (0-8 h). Samples were subjected for Western immunoblotting for 27KIP1 protein.
Expression of the Erk2 protein was used for protein loading control
Androgens inhibit Bcl-2 expression via RB H Huang et al Figure 9 The effect of expression of p15INK4B and p27KIP1 on androgen-induced suppression of Bcl-2. (a) Forced expression of p15INK4B and/or p27KIP1 inhibits Bcl-2 expression in LNCaP cells. LNCaP cells (5 Â 10 6 ) were transiently transfected with expression plasmids for p15INK4B (2 mg), p27KIP1 (2 mg), p15INK4B plus p27KIP1 (1 mg each), or the control vector pcDNA3.1. At 48 h post-transfection, cells were collected and lysated. A measure of 50 mg of proteins from each sample were separated by 4-12% SDS-PAGE gel under reducing conditions. Immunoblots were blotted sequentially with antibodies against Bcl-2, E2F1, p15INK4B, p27KIP1, Ser780-p-RB, and Ser795-p-RB. Immunoblotting with an antibody to ErK2 was performed for a loading control. Data are from a representative experiment performed three times. (b) The effect of p15INK4B and p27KIP1 on the activities of the Bcl-2 promoter reporters. LNCaP cells (1 Â 10 6 ) were transfected with 2 mg of luciferase reporters of pGL3-Prom, pBcl2(E2F-v), or pBcl-2(mE2F-v) along with the empty vector (pcDNA3.1), p15INK4B (1 mg), p27KIP1 (1 mg), or p15INK4B plus p27KIP1 (0.5 mg each). At 36 h post-transfection, cells were collected and lysated. Firefly luciferase activities were measured in each sample. A renilla luciferase vector was used as an internal control. The luciferase activities of the Bcl-2 promoters were normalized to the activity of the backbone vector pGL3-Prom. Data represent the mean values þ standard deviation of three independent experiments. (c) and (d) RNA inference of p15INK4B (c) or p27KIP1 (d) reduces the inhibitory effect of androgens on the expression of E2F1 and Bcl-2. LNCaP cells grown in log phase were transfected with a pool of siRNAs for p15INK4B, p27KIP1, or a pool of nonspecific control siRNAs. At 24 h after transfection, cells were treated with 1 nM of R1881 or ETOH. After 48 h, cells were collected and lysated for Western immunoblotting for p15INK4B, p27KIP1, E2F1, Bcl-2, or ErK2
Androgens inhibit Bcl-2 expression via RB H Huang et al of RB. Thus, our data demonstrate that suppression of Bcl-2 expression by androgens in prostate cancer cells is mediated by androgen-induced activation of the CDKI-RB axis, which results in a decrease in the binding of E2F1 protein to the E2F site in the Bcl-2 promoter.
Two promoters, P1 and P2, have been identified previously for the Bcl-2 gene. In the majority of cell systems examined so far, expression of Bcl-2 is regulated mainly through P1 (Seto et al., 1988; Miyashita et al., 1994; Wilson et al., 1996) . This appears to be the case in prostate cancer cells since it has been shown recently that both PTEN and WT1 regulates Bcl-2 expression through P1 (Huang et al., 2001; Cheema et al., 2003) . In this study, an androgen-regulated region was identified in the same promoter, indicating that the androgenic effect is also mediated through P1. Within the androgenregulated region, however, no consensus ARE was found, which provides further support to a previous study in breast cancer (Seto et al., 1988; Lapointe et al., 1999; Bruckheimer et al., 2003) . This result is consistent with our finding that the effect of androgens on expression of Bcl-2 mRNA is blocked by the inhibition of protein synthesis. Recently, two possible AREs, which have 60-80% homology to the consensus ARE, have been reported in the P2 promoter (Bruckheimer et al., 2003) . However, whether or not the AR binds to the P2 promoter and thereby regulates its activity has yet to be determined (Bruckheimer et al., 2003) .
We also provide direct evidence that androgens modulate Bcl-2 expression by regulating the binding of E2F1 to an E2F site. Mutations in the E2F site abolished the androgenic effect on Bcl-2 expression. Moreover, transient and stable expression of E2F1 blocked androgen-induced downregulation of Bcl-2. It is worth noting that this E2F site is different from the consensus E2F-binding sequence (Johnson et al., 1994; Neuman et al., 1994) . However, it matches perfectly with one identified in the promoter of the p21WAF1 gene (Hiyama et al., 1998) . The same E2F-binding sequence (8 bp) was identified previously in the Bcl-2 promoter (Gomez-Manzano et al., 2001) . By using ChIP assays, however, our data demonstrate for the first time that E2F1 binds to this E2F site in its natural setting, since the oligonucleotide (25 bp) used for electrophoretic gel mobility shift assays originated from the promoter of p21WAF1 rather than Bcl-2 (Gomez-Manzano et al., 2001).
We also define the RB protein as an important mediator in the regulation of Bcl-2 by androgens. First we observed that androgen-induced downregulation of Bcl-2 is associated with activation of the RB protein. Furthermore, we demonstrated that ectopic expression of RB inhibited expression of the Bcl-2 protein and activity of the Bcl-2 promoter. Additionally, knockdown of endogenous RB protein induced upregulation of Bcl-2. Importantly, we demonstrated that androgen-induced suppression of Bcl-2 expression was abolished by specific inactivation of RB function by the mutated E1A. Recently, Decary et al. (2002) demonstrated that overexpression of RB protein transactivates expression of the Bcl-2 gene in kidney and breast epithelial cells and that this activation is mediated the P2 promoter. The transactivation of Bcl-2 by RB relies completely on expression of the AP2 transcription factor, since no effect of RB on Bcl-2 expression has been found in cells without AP2 expression (Decary et al., 2002) . Indeed, no AP2 mRNA has been detected by Northern blot analyses in either LNCaP or PC-3 prostate cancer cells (Butler et al., 2000) . Therefore, the lack of AP2 expression in LNCaP and PC-3 cells might affect the transactivational property of RB in these cells. Thus, RB-mediated regulation of Bcl-2 expression in prostate cancer cells might be a cell-type dependent event. Figure 10 Androgen-induced inhibition of Bcl-2 expression prior to G1 arrest. At 48 h after plating, LNCaP cells (50% confluence) were treated with 1 nM of R1881 or ethanol. Cells were harvested at the time points as indicated. Collected cells were split into two groups. (a) One group was used for cell cycle analysis, and (b) the other group was used for Western blot analysis of expression of E2F1 and Bcl-2. For cell cycle analysis, cells were fixed with icecold 70% ethanol, and stained with propidium iodide (50 mg/ml). Cell cycle distributions were determined by flow cytometry and analysed by ModFit II software. Western blot analysis of Bcl-2 and E2F1 was performed as described in Figure 1a and 4a, respectively Androgens inhibit Bcl-2 expression via RB H Huang et al
In addition to modulating E2F1 regulation of Bcl-2, we also found that other E2F1-regulated genes such as p107 and cyclin A are decreased by androgens in LNCaP cells. These findings suggest that androgen independency may result in loss of the negative impact of androgens on E2F1 activity, thereby leading to Bcl-2 overexpression. It has been speculated that overexpression of Bcl-2 in androgen-refractory prostate cancer is due to loss of the inhibitory effect of androgens on Bcl-2 under androgen ablation conditions (McDonnell et al., 1992) . Indeed, androgen withdrawal causes upregulation of Bcl-2 in LNCaP cells (Gleave et al., 1999a; Huang et al., 2001) . Importantly, the proteins identified in this study that are involved in androgenic regulation of Bcl-2 are also deregulated during androgen-independent progression of prostate cancer. In the CWR22 xenograft model, androgen deprivation results in an increase in E2F1 expression and a decrease in RB activity (Agus et al., 1999) . Moreover, the CDKI p27KIP1 is downregulated in androgen-refractory sublines of LNCaP in comparison to parental cells (Graff et al., 2000; Murillo et al., 2001) . Also, p27KIP1 is frequently lost in advanced prostate cancer (Cordon-Cardo et al., 1998; Yang et al., 1998) . Therefore, our findings appear to reflect the changes occurring in androgen-refractory tumors. Thus, further studies of Bcl-2 expression and the androgenic regulatory mechanism may lead to new prognostic and therapeutic paradigms.
Materials and methods
Plasmids
Bcl-2 luciferase reporter constructs LB124, LB334, and LB360 were kindly provided by Dr LM Boxer (Wilson et al., 1996) . These constructs contain a series of deletions in the Bcl-2 5 0 promoter (P1) that were cloned into the luciferase vector pBluescript II (Stratagene). These deletions all terminate at the restriction site SacI, À1293 bp from the Bcl-2 translation start site (see Figure 2b) . pBcl2m-Luc, pBcl2(E2F-v), and pBcl2(mE2F-v) were generated by the polymerase chain reaction (PCR). Based on the genomic sequence of the Bcl-2 gene (accession number NT_033907), pBcl2m-Luc was constructed by cloning a DNA fragment À1646 to -1532 into a pGL3-Basic vector (Promega) between the XhoI and HindIII sites. pBcl2(E2F-v) was constructed by cloning a DNA fragment À1483 to À1405 into a pGL3-promoter vector (Promega) between the MluI and BglII sites. pBcl2(mE2F-v) was derived from pBcl2(E2F-v) by introducing two point mutations into a putative E2F element [À1452(CTCCGCGC) was converted to À1452(CTCCGATC)]. A mammalian expression vector for human AR gene was constructed with a pCMV5 backbone vector. Promoter luciferase reporter constructs for the human E2F1 gene, including E2F1 (À728), E2F1 (À242), E2F1 (À204), and E2F1 (À122), were kindly provided by Dr JR Nevins (Johnson et al., 1994) . A full-length luciferase reporter construct of the p15INK4B promoter (p15P751-luc) was characterized previously and provided by Dr XF Wang (Li et al., 1995) . An expression vector for a constitutively active form of RB protein (pcDNA3-RbDK11) was a gift from Dr E Zacksenhaus (Jiang and Zacksenhaus, 2002) . Expression vectors for wild-type adenoviral E1A (12S), mutants RG2 and YH47/CG124 as well as an empty vector were kindly provided by Dr RJ Kelm (Liu et al., 2000) . The coding regions of cDNAs for human E2F1, p15INK4B, and p27KIP1 were amplified from a normal human prostate cDNA library and cloned into a expression vector pcDNA3.1( þ ) (Invitrogen). Plasmids used in this study were confirmed by sequence analysis. Nucleotide sequences of the Bcl-2 promoter described in this study are numbered by their positions relative to the translation start site (designated as þ 1) based upon the updated sequence of the Bcl-2 gene (accession number NT_033907).
Antibodies
Mouse monoclonal antibodies to Bcl-2 (100), E2F1 (KH95), E1A (M73), p27KIP1 (F-8), Erk2 (D-2), and polyclonal antibodies to , E2F1 (C-20), p16INK4 (C-20), Bax (I-19), Skp2 (H-435), p107 (C-18), were purchased from Santa Cruz Biotechnology. Mouse monoclonal antibodies to AR (#554225), RB (#554136), and cyclin A (#554174) were purchased from BD PharMingen. Polyclonal antibodies to Phospho-RB at serine 780 (Ser780-p-RB; #9307) and serine 795 (Ser795-p-RB; #9301) were purchased from Cell Signaling Technology. Monoclonal antibodies to p15INK4B (Ab-3) and p21WAF1 (Ab-1) were purchased from Oncogene Research Products. A monoclonal antibody to PSA (M0750) was purchased from Dako.
Cell lines and culture conditions
Human prostate cancer cell lines LNCaP and PC-3 were purchased from American Tissue and Cell Culture (ATCC). LNCaP/Neo and LNCaP/E2F1 stable cell lines were generated by transfecting LNCaP cells with a pcDNA3.1 empty vector and a pcDNA3.1-E2F1 expression vector, respectively, and selected by treating cells with 500 mg/ml of G418 (Sigma).
Cell transfections
PC-3 cells grown in log phase were transfected with a mammalian expression vector for human AR (pCMV5-AR) using a Lipofectamine Plus reagent (Invitrogen) according to the instructions provided by the manufacture. Transfection of LNCaP cells was performed by electroporation. Total plasmid DNA (20 mg) was kept constant for all transfections by adding empty vectors and pEGFP-N1 plasmid (1 mg). Cells were mixed with DNA in 400 ml of RPMI 1640 medium. The DNAcell mixture was transferred into a 4-mm cuvette (BTX Inc., San Diego, CA, USA) and electroporated with a 306 V/10 ms pulse using a BTX T820 square wave electroporator (BTX Inc., San Diego, CA, USA). Transfection efficiency was monitored at 12 h after transfection by examining aliquots of cells under a Zeiss fluorescence microscope at a wavelength of 488 nm. Transfection efficiency was determined by the percentage of green cells in the whole-cell population. Routinely, transfection efficiencies of 60-90% were obtained. SMARTpools of siRNA specific for p15INK4B (M-003245-00-05), p27KIP1 (M-003472-00-05), or nonspecific control RNA duplex (D-001206-13-05) were purchased from Dharmacon Inc. (Lafayette, CO, USA). LNCaP cells (5 Â 10 5 ) were plated into six-well plates. Cells grown at logarithmic phase were transfected with Oligofectamine Reagents (Invitrogen) and gene-specific or nonspecific control siRNAs at a final concentration of 100 nM.
Transcription assays
Northern blot analyses of expression of the Bcl-2, E2F1, p15INK4B, and p27KIP1 messenger RNAs were performed by following a method described previously . Briefly, cells treated with androgens/ETOH or transfected with a pcDNA3.1-E2F1/empty vector were collected, and total RNA was isolated using the TRIZOL reagent (Invitrogen). Aliquots (15 mg) of cellular RNA were separated on 1.2% denaturing formaldehyde-agarose gels and transferred to nylon membranes. For Northern hybridization, a cDNA fragment (293 bp) of the human Bcl-2 gene was amplified from a plasmid (pB4, purchased from ATCC) that contains the entire open reading frame of Bcl-2 by using a pair of primers (RDP-44-025) obtained from R&D Systems (Minneapolis, MN, USA) . A SalI-XhoI fragment (B0.8 kb) of the coding region of the human E2F1 gene, a SpeI-KpnI fragment (B0.3 kb) of the coding region of the human p15INK4B gene, and the entire coding region of human p27KIP1 gene were purified and labeled as probes for Northern hybridization analysis of E2F1, p15INK4B, and p27KIP1, respectively. After stripping with a sterile H 2 O/0.5% SDS solution for 10 min at 90-1001C, blots were reprobed with a [ 32 P]dATP-labeled cDNA fragment of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as described previously (Huang et al., 1999) . Activities of luciferase reporter constructs for the promoters of Bcl-2 and E2F1 were determined by using luciferase reporter assays. Cells were harvested at 36 h after transfections, and cell lysates were prepared by adding lysis buffer directly to the cells on ice. Firefly luciferase and renilla luciferase activities were determined using a dual-luciferase kit (Promaga, Madison, WI, USA), and renilla luciferase activities of cells were used as internal controls.
Western blot analysis
Protein samples were prepared by lysing cells in RIPA buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium deoxycholate, 150 mM NaCl, 1 mM EGTA, 1 mM PMSF, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 1 mg/ml pepstatin, 1 mM Na 3 VO 4 , and 1 mM NaF). Equal amounts of protein (15-50 mg) from cell lysates were denatured in sample buffer, subjected to SDS/PAGE on 8, 12, or 4-20% gels (Invitrogen, Carlsbad, CA, USA), and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA, USA). The filters were immunoblotted with specific primary antibodies, HRPconjugated secondary antibodies, and visualized by enhanced chemiluminescence (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
ChIP assay
ChIP assays were performed by modifying methods published previously (Weinmann et al., 2001; Masiello et al., 2002) . LNCaP cells (1 Â 10 7 ) grown to 70% of confluence were transfected with pcDNA3.1-E2F1 expression vector by electroporation. Transfected cells were plated onto two 100-mm TC dishes. At 36 h after plating, formaldehyde was added directly to tissue culture medium to a final concentration of 1%. Cells were incubated on a shaking platform for 10 min at room temperature. After rinsing twice with ice-cold 1 Â PBS, crosslinking was terminated by scraping cells into 1 ml of termination solution (100 mM Tris, pH 9.4, 10 mM dithiothreitol) and incubated at 301C for 15 min. Cell pellets were washed twice with 1 Â PBS and resuspended in 0.3 ml of lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris, pH 8, and 1 Â protease inhibitor cocktail from Sigma). Chromatin DNA was sheared to 400-1000 bp with three sequential 10-s pulses with a microtip ultrasonic cell dismembrator (Branson Sonifer 250, VWR) at 70% of duty cycle and microtip limit 7 of output control. Cell debris was pelleted at 10 000 g, and the supernatant fluid was added to 10 mg of sheared herring sperm DNA, 20 ml of nonimmunue sera (goat), and 20 ml of 50% slurry of immobilized protein-A (IPA-300, RepliGen) and rotated at 41C for 30 min. Prior to immunoprecipitation, 20% of the precleared supernatant was saved as total input chromatin DNA and processed with the eluted immunoprecipitates beginning at the crosslink reversal step. Immunoprecipitation was performed by adding 1 mg of rabbit anti-E2F1 polyclonal antibody (C-20, Santa Cruz Biotechnology), 2 mg of sheared herring sperm DNA, and 20 ml of 50% slurry of immobilized protein-A. Control immunoprecipitations contained 1 mg of a nonspecific rabbit IgG (Vector Laboratories). Precipitates were washed three times with washing solution (300 mM NaCl, 50 mM Tris, pH 8, 2.7 mM KCl, 0.05% Tween 20, and 1% deoxycholate), and an additional three times with TE buffer (10 mM, 1 mM EDTA). Beads were eluted three times with 35 ml of 1% SDS and 100 mM NaHCO 3 at 371C for 10 min each. Samples (adding NaHCO 3 to the input samples to final concentration of 100 mM) were incubated at 651C overnight to reverse crosslink the DNA. Products were purified with QIAquick PCR purification spin resin (Qiagen), and 10% of the eluate was subjected to PCR amplification with 35 cycles of 951C for 30 s, 601C 30 s, and 721C 40 s. The forward 5 0 -CGGGTGGCTCAGAGGAGG-3 0 and reverse primer 5 0 -ACCTTCGCTGGCAGCGG-3 0 correspond to nt À1603 to À1586 and nt À1360 to À1376, respectively, in the Bcl-2 promoter, which flank a putative E2F site (À1452 to À1445). PCR products were analysed by 5% agarose gels and stained with ethidium bromide. ) were grown on CELLocate coverslips (Eppendorf Scientific, Inc., Hamburg, Germany), 175 mm square. Microneedles were prepared fresh from borisilicate glass capillaries (1.0 nm outer diameter; 0.78 nm inner diameter) using a Flamingo/Brown micropipette puller P-97 (Sutter Instruments, Novato, CA, USA) and loading micropipettes were pulled manually. Cells were injected with 40 mM of a double-stranded small interference Rb siRNA. siRNA and control samples were prepared in microinjection buffer (10 mM KH 2 PO 4 , pH 7.2, and 75 nM KCL). Texas dextran (red) was added to all microinjection solutions. This served as an indicator for successful microinjection and enabled the identification of injected cells by confocal microscopy after functional assays were performed. The injection volume was approximately 5% of the total cell volume. Microinjections were performed using a microscope stage, and cells were allowed to recover 4-6 h at 371C in a 5% CO 2 incubator before subsequent manipulations. Images were obtained using an intensified charged coupled device camera (Hamamatsu) attached to a Zeiss Axiovert 35 microscope (Carl Zeiss, Inc., Germany).
Immunofluorescence and confocal microscopy
Cells on coverslips (Eppendorf Scientific, Inc., Hamburg, Germany) were washed briefly in 1 Â PBS and fixed for 20 min in 2% paraformaldehyde (Toussins) in 1 Â PBS. For studies involving double staining, cells were permeabilized by incubating with 0.3% Triton X-100 for 3 min. Cells were washed three times in 1 Â PBS, and incubated in blocking buffer (5% goat serum in 1 Â PBS) for 1 h at room temperature. Cells were incubated with a rabbit anti-Bcl-2 polyclonal antibody (1 : 250) and a mouse anti-RB monoclonal antibody (1 : 250) for 2 h at room temperature. After washing with 1 Â PBS three times for 5 min each, cells were incubated for 1 h at room temperature with the following secondary antibodies: Alexa Fluor 350 goat anti-rabbit IgG conjugate (Molecular Probes, Inc.) (1 : 1000), and Alexa Fluor 488 goat anti-mouse IgG conjugate (Molecular Probes, Inc.) in blocking buffer for 1 h at room temperature. Coverslips were washed with three changes of 1 Â PBS for 5 min each and mounted in ProLong (Molecular Probes, Inc.). Injected cells were analysed with a laser-scanning microscope LSM510 (Carl Zeiss, Inc., Germany). Argon Ion and HeNe lasers were used to excite FITC and Texas red fluorescence, respectively.
Cell cycle analysis
LNCaP cells were treated with 1 nM of R1881 or ETOH. At different time points after treatment, cells were trypsinized and fixed in freshly prepared ice-cold 70% ethanol for 30 min.
After washing with 1 Â PBS, cells (1 Â 10 6 ) were stained with 1 Â PBS solution containing 50 mg/ml propidium iodide and 50 mg/ml RNase A at room temperature for 30 min. Cell cycle distributions were determined by flow cytometric analysis using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA), and analysed by ModFit II software.
Abbreviations AR, androgen receptor; ARE, androgen response element; RB, retinoblastoma protein; CDK, cyclin-dependent kinase; CDKI, cyclin-dependent kinase inhibitor; ChIP, chromatin immunoprecipitation; siRNA, small interference RNA.
